Company Quick10K Filing
Rewalk Robotics
S-1 2020-01-15 Public Filing
S-1 2020-01-15 Public Filing
10-K 2019-12-31 Filed 2020-02-20
10-Q 2019-09-30 Filed 2019-11-13
10-Q 2019-06-30 Filed 2019-08-09
10-Q 2019-03-31 Filed 2019-05-08
10-K 2018-12-31 Filed 2019-02-08
S-1 2018-10-15 Public Filing
10-Q 2018-09-30 Filed 2018-11-08
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-03-08
10-Q 2017-09-30 Filed 2017-11-02
10-Q 2017-06-30 Filed 2017-08-03
10-Q 2017-03-31 Filed 2017-05-04
10-K 2016-12-31 Filed 2017-02-17
10-Q 2016-09-30 Filed 2016-11-03
10-Q 2016-06-30 Filed 2016-08-04
10-Q 2016-03-31 Filed 2016-05-10
10-K 2015-12-31 Filed 2016-02-29
20-F 2014-12-31 Filed 2015-02-27
8-K 2020-03-19 Officers
8-K 2020-03-02 Officers
8-K 2020-02-20 Earnings, Exhibits
8-K 2020-02-05 Enter Agreement, Other Events, Exhibits
8-K 2019-11-13 Earnings, Exhibits
8-K 2019-08-08 Earnings, Exhibits
8-K 2019-06-10 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2019-06-05 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2019-05-14 Officers, Regulation FD, Exhibits
8-K 2019-05-09 Enter Agreement, Exhibits
8-K 2019-05-07 Earnings, Exhibits
8-K 2019-04-23 Earnings, Other Events
8-K 2019-04-03 Enter Agreement, Earnings, Sale of Shares, Other Events, Exhibits
8-K 2019-03-27 Shareholder Rights, Amend Bylaw, Shareholder Vote, Other Events, Exhibits
8-K 2019-02-08 Earnings, Exhibits
8-K 2019-02-07 Other Events
8-K 2019-01-14 Earnings, Exhibits
8-K 2018-11-16 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-11-13 Regulation FD, Exhibits
8-K 2018-11-08 Earnings, Exhibits
8-K 2018-10-26
8-K 2018-10-15 Earnings
8-K 2018-08-14 Earnings, Exhibits
8-K 2018-07-23 Earnings, Other Events
8-K 2018-06-29 Other Events, Exhibits
8-K 2018-06-06 Other Events
8-K 2018-05-17
8-K 2018-05-15 M&A, Officers, Regulation FD, Exhibits
8-K 2018-05-06 Earnings, Officers, Exhibits
8-K 2018-05-02 Officers, Regulation FD, Exhibits
8-K 2018-04-30 Shareholder Vote
8-K 2018-03-23 Other Events, Exhibits
8-K 2018-03-13 Other Events
8-K 2018-03-06 Enter Agreement, Earnings, Sale of Shares, Regulation FD, Exhibits
8-K 2018-03-01 Officers, Exhibits
8-K 2018-02-21 Enter Agreement, Sale of Shares, Other Events, Exhibits
8-K 2018-01-11 Other Events
8-K 2018-01-01 Officers, Regulation FD, Exhibits

Rewalk Robotics Financials

RWLK Metrics, Comps, Filings

Quarterly | Annual

Business

We are an innovative medical device company that is designing, developing and commercializing robotic exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. We have developed and are continuing to commercialize ReWalk, an exoskeleton designed for individuals with paraplegia that uses our patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. Additionally, we are developing and intend to commercialize a lightweight soft exo-suit, designed to support mobility and/or therapy for individuals suffering from other lower limb disabilities such as stroke, multiple sclerosis, cerebral palsy, Parkinson's disease and elderly assistance.

Development of ReWalk took over a decade and was spurred by the experiences of our founder, Dr. Amit Goffer, who became a quadriplegic due to an accident. Current ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, who have the use of their upper bodies and arms. We currently offer two products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is currently designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is currently designed for use by paraplegia patients in the clinical rehabilitation environment, and provides valuable exercise and therapy. ReWalk Rehabilitation also enables individuals to evaluate their capacity for using ReWalk Personal in the future. In 2011, we launched ReWalk Rehabilitation for use in hospitals and rehabilitation centers in the United States and Europe. We began marketing ReWalk Personal in Europe with CE mark clearance at the end of 2012 and received U.S. Food and Drug Administration, or FDA, clearance to market it in the United States in June 2014. Additionally, we have received regulatory approval to sell the ReWalk device in other countries. In the future we intend to seek approval from the applicable regulatory agencies in other jurisdictions where we may seek to market ReWalk.

ReWalk is a breakthrough product that can fundamentally change the health and life experiences of users. Designed for all-day use, ReWalk is battery-powered and consists of a light, wearable exoskeleton with integrated motors at the joints, an array of sensors and a computer-based control system to power knee and hip movement. ReWalk controls movement using subtle shifts in the user's center of gravity. A forward tilt of the upper body is sensed by the system, which initiates the first step. Repeated body shifting generates a sequence of steps that results in a functional walking speed. Because the exoskeleton supports its own weight and facilitates the user's gait, users do not expend unnecessary energy while walking. While ReWalk does not allow side-to-side actuation, users are able to turn by shifting their weight to the side. ReWalk also allows users to sit, stand and, depending on local regulatory approvals, climb and descend stairs. Use on stairs is not cleared by the FDA in the United States. ReWalk users are able to operate the devices independently, and most are able to put on and remove the devices by themselves. Our safety guidelines and FDA specifications, however, require users to be accompanied by a trained companion at all times when using ReWalk.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Quarterly)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Quarterly)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Conformis (CFMS) 127,869 48% -4.3 -45% 73,289 53,389 79,589 37,949 -32,915 -27,325 117,871
Northern Technologies International (NTIC) 113,086 32% 16.5 8% 67,511 10,916 55,750 17,780 5,663 6,518 107,229
Invacare (IVC) 260,927 28% 75.7 -4% 847,405 531,926 939,627 262,330 -35,889 5,263 398,168
Lakeland Industries (LAKE) 96,208 34% 15.9 2% 99,104 14,863 79,620 27,271 2,076 5,578 88,423
Shiloh Industries (SHLO) 94,685 9% 7.8 -3% 651,691 484,177 1,054,707 90,576 -19,947 42,453 329,060
Virco Manufacturing (VIRC) 66,783 39% 4.8 5% 139,865 75,316 164,250 64,668 6,692 16,737 80,443
Precision Therapeutics (AIPT) 13,264 72% 105.9 0% 5,416 2,389 1,320 951 0 123 13,054
Alpha Pro Tech (APT) 48,716 37% 11.9 7% 37,864 4,621 35,746 13,130 2,665 3,665 43,610
Hudson Technologies (HDSN) 28,561 10% -18.2 -11% 204,206 149,253 162,027 15,484 -23,276 -6,358 116,006
Rewalk Robotics (RWLK) 23,214 54% -0.8 -42% 28,426 14,311 3,692 2,010 -11,976 -11,972 9,493
Nanovibronix (NAOV) 19,155 69% -3.7 -150% 3,070 840 443 307 -4,601 -4,568 16,897
Milestone Scientific (MLSS) 47,202 69% -10.0 -75% 6,243 7,647 6,074 4,179 -4,661 -4,564 45,491
Myomo (MYO) 13,064 73% -1.1 -131% 6,083 1,664 2,317 1,696 -7,952 -7,952 8,660
Industrial Services of America (IDSA) 9,385 1% -9.3 -13% 24,547 16,631 41,558 276 -3,228 -1,712 15,855
Allied Healthcare Products (AHPI) 8,790 17% -10.1 -10% 15,479 4,202 32,089 5,420 -1,489 -838 8,487
XPEL (XPEL) 35% -0.7 16% 47,406 17,347 65,712 22,899 7,517 10,348 -6,897
Predictive Oncology (POAI) 62% 0.0 -8% 31,882 11,168 1,064 664 -2,543 -2,060 -99
Ocugen (OCGN) 0.4 -150% 23,619 36,712 0 -900 -35,424 -34,628 -14,394
BRP (DOOO)
Steel Partners Holdings (SPLP) 32% 2.0 1% 2,345,718 1,828,035 1,197,598 388,309 33,977 151,171 301,966

Balance Sheet ($'000)2015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash17,86921,80915,68612,39923,67817,12816,25512,92814,5679,6689,9316,06910,3479,67424,86421,147
Accounts Receivable2,1462,4411,1879441,2541,4011,1141,2651,1031,5661,8571,1637581,092417572
Inventory2,5343,0603,4153,4253,2643,0473,4153,5003,6433,4803,0162,4722,2402,4782,6612,980
PP&E2,1011,2941,4511,3462,7041,1171,0689062,9287567627283,177532453480
Assets25,57431,09924,63820,81931,76325,27424,32121,48422,86317,72017,02511,87414,96217,03631,97228,426
Accounts Payable2,4742,8524,2393,4453,4242,9862,9102,4261,8112,8732,9572,7782,3282,7562,8173,043
Long-Term Debt10,14110,30710,47918,01316,87815,97815,66615,35214,23713,08112,4223008,2867,8667,426
Liabilities4,65415,18516,58816,11723,50321,93220,91820,14419,15619,21918,28917,09513,01714,98114,70414,311
Stockholders' Equity20,92015,9148,0504,7028,2603,3423,4031,3403,707-1,499-1,264-5,2211,9452,05517,26814,115
Income Statement ($'000)2015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue2,0618171,4001,5912,4992,0071,7321,5151,5791,7701,6171,5818771,234
Cost of Revenue1,5687321,1101,7231,4501,2661,0249128971,003855655442585
Gross Profit49385290-1321,049741708603682767762926435649
R&D1,6953,0741,9682,2911,4301,3851,6181,6092,1512,4301,5971,4141,8601,018
SG&A5,2135,5995,7255,6125,2744,7234,4424,6124,3734,3783,2883,0872,8102,662
Tax18129-3614-415940057-1-2
Net Income-6,922-9,117-7,920-8,544-6,400-6,309-5,846-6,162-6,327-5,798-4,533-4,000-4,587-3,389
Cash Flow ($'000)2015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-6,937-6,576-6,687-7,337-6,050-5,181-5,841-5,426-5,026-4,042-3,106-4,253-3,703-3,269
Cash Investing-129-266-13-29-10-123-20-30-8
Cash Financing11,0067193,41318,645-4904,3202,5117,067-7294,308-7563,58018,893-440